Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 15/20 | 0.73 |
| ▸ | STAMBP | O95630 | 12/20 | 0.73 |
| ▸ | COPS5 | Q92905 | 10/20 | 0.73 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18526836 | 0.85 | PSMD14 (1.00) | PSMD14STAMBPCOPS5 | |
| SCHEMBL18539634 | 0.77 | PSMD14 (0.68) | PSMD14STAMBPCOPS5HPGDS | |
| SCHEMBL18539636 | 0.76 | PSMD14 (0.73) | PSMD14STAMBPCOPS5HPGDS | |
| SCHEMBL18539638 | 0.74 | PSMD14 (0.74) | PSMD14STAMBPCOPS5 | |
| SCHEMBL13858023 | 0.73 | PSMD14 (0.65) | PSMD14STAMBPCOPS5HPGDS | |
| SCHEMBL18539641 | 0.73 | PSMD14 (0.76) | PSMD14STAMBPCOPS5 | |
| SCHEMBL13977542 | 0.72 | PSMD14 (0.66) | PSMD14STAMBPCOPS5HPGDS | |
| SCHEMBL8124745 | 0.72 | NAMPT (0.60) | PSMD14STAMBPCOPS5NAMPTCSNK2A2 | |
| SCHEMBL18539646 | 0.71 | STAMBP (0.73) | PSMD14STAMBPCOPS5 | |
| SCHEMBL13978048 | 0.71 | PSMD14 (0.72) | PSMD14STAMBPCOPS5HPGDSNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2017031255-A1 | INHIBITORS OF RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050931-A1 | INHIBITORS OF RPN11 | POLR2A, RPP30, RPIA | PSMD14 418/4885STAMBP 3835/4885COPS5 700/4885 |
| US-10005735-B2 | Inhibitors of RPN11 | POLR2A, RPP30, RPIA | PSMD14 418/4885STAMBP 3835/4885COPS5 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.